The Mass Spectrometry Core will provide the powerful tools of modern mass spectrometry to DPPG investigators. Quantification of both lipids and oxidized amino acids by GC/MS remains a mainstay of the Core. The Core will also permit structural identification and quantitation of high density lipoprotein (HDL)- related biomolecules, including apolipoprotein A-l and serum amyloid protein. Over the past two years, Core personnel have also become proficient in 2-dimensional liquid chromatography-electrospray ionization- MS/MS analysis (shotgun proteomics) of complex biological mixtures of proteins, and we anticipate that all investigators will take advantage of this capability in the next funding period. In addition to providing instrumental capabilities, Mass Spectrometry Core staff will provide consultation and collaboration on the application of mass spectrometry to the DPPG research program, and this will include development of new analytical methods targeted at achieving research objectives of DPPG investigators. The Mass Spectrometry Core will optimize the efficiency and cost-effectiveness through which these services are provided to DPPG investigators by providing a central laboratory. This avoids the need for individual DPPG investigators to maintain the required instrumentation in their own laboratories and avoids the high cost of commercial mass spectrometric services. By centralizing and standardizing procedures, the Mass Spectrometry Core will provide a common set of analytical tools that will lead to a unified understanding of molecular mechanisms involved in physiologic and pathophysiologic processes of diabetic vascular disease.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL092969-50
Application #
8105148
Study Section
Special Emphasis Panel (ZHL1)
Project Start
Project End
Budget Start
2010-06-01
Budget End
2011-05-31
Support Year
50
Fiscal Year
2010
Total Cost
$149,344
Indirect Cost
Name
University of Washington
Department
Type
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Tannock, Lisa R; De Beer, Maria C; Ji, Ailing et al. (2018) Serum amyloid A3 is a high density lipoprotein-associated acute-phase protein. J Lipid Res 59:339-347
Wall, Valerie Z; Barnhart, Shelley; Kanter, Jenny E et al. (2018) Smooth muscle glucose metabolism promotes monocyte recruitment and atherosclerosis in a mouse model of metabolic syndrome. JCI Insight 3:
Kanter, Jenny E; Kramer, Farah; Barnhart, Shelley et al. (2018) A Novel Strategy to Prevent Advanced Atherosclerosis and Lower Blood Glucose in a Mouse Model of Metabolic Syndrome. Diabetes 67:946-959
Yuan, Chujun; Hu, Jiyuan; Parathath, Saj et al. (2018) Human Aldose Reductase Expression Prevents Atherosclerosis Regression in Diabetic Mice. Diabetes 67:1880-1891
Rune, Ida; Rolin, Bidda; Lykkesfeldt, Jens et al. (2018) Long-term Western diet fed apolipoprotein E-deficient rats exhibit only modest early atherosclerotic characteristics. Sci Rep 8:5416
Shao, Baohai; Heinecke, Jay W (2018) Quantifying HDL proteins by mass spectrometry: how many proteins are there and what are their functions? Expert Rev Proteomics 15:31-40
Basu, Debapriya; Hu, Yunying; Huggins, Lesley-Ann et al. (2018) Novel Reversible Model of Atherosclerosis and Regression Using Oligonucleotide Regulation of the LDL Receptor. Circ Res 122:560-567
Scolaro, Bianca; Nogueira, Marina S; Paiva, Aline et al. (2018) Statin dose reduction with complementary diet therapy: A pilot study of personalized medicine. Mol Metab 11:137-144
Fang, Xiang; Dorcely, Brenda; Ding, Xi-Ping et al. (2018) Glycemic reduction alters white blood cell counts and inflammatory gene expression in diabetes. J Diabetes Complications 32:1027-1034
Wight, Thomas N (2018) A role for proteoglycans in vascular disease. Matrix Biol 71-72:396-420

Showing the most recent 10 out of 136 publications